Testosterone supplementation did not show consistent benefit for cardiovascular risk , sexual function , mood and behavior , or cognition .
Studies that examined clinical cardiovascular endpoints have not favored testosterone therapy over placebo .
Testosterone is ineffective in treating erectile dysfunction and controlled trials did not show a consistent effect on libido .
Testosterone supplementation consistently increased muscle strength but did not have beneficial effects on physical function .
Most studies on mood-related endpoints found no beneficial effect of testosterone treatment on personality , psychological well-being , or mood .
Testosterone products are recommended by some prescribers in response to a diagnosis or presumption of " low testosterone " ( low-T ) for cardiovascular health , sexual function , muscle weakness or wasting , mood and behavior , and cognition .
The effect of testosterone on health-related quality of life in elderly males - a pilot study.
OBJECTIVE To assess the effect of short-term testosterone supplementation on health-related quality of life in elderly males . METHOD As part of a double-blind , placebo-controlled study , healthy males > or = 65-year-old were r and omised to receive a total of four doses of 200 mg testosterone enanthanate ( n = 14 ) or placebo ( n = 8) intramuscularly every 2 weeks . Health-related quality of life ( HRQOL ) was assessed using the Short Form 36-item ( SF-36 ) and Psychological General Well-Being ( PGWB ) scales , at baseline , week 8 and during therapy withdrawal , 6 weeks after the last dose . RESULTS The baseline SF-36 scores were similar between the groups in seven domains ; only vitality was significantly lower in the placebo group ( T : 80.4 , P : 65.6 ; P = 0.007 ) . After the 8-week treatment period and withdrawal phase , SF-36 scores were not significantly different between the groups . The PGWB scores at baseline , on treatment and off treatment were not significantly different between the groups . Moreover , the SF-36 and PGWB scores within each group did not change significantly over time . CONCLUSION This pilot study suggests that intramuscular testosterone , administered at a dose of 200 mg every 2 weeks , does not affect the HRQOL of elderly males
Testosterone supplementation did not show consistent benefit for cardiovascular risk , sexual function , mood and behavior , or cognition .
Studies that examined clinical cardiovascular endpoints have not favored testosterone therapy over placebo .
Testosterone is ineffective in treating erectile dysfunction and controlled trials did not show a consistent effect on libido .
Testosterone supplementation consistently increased muscle strength but did not have beneficial effects on physical function .
Most studies on mood-related endpoints found no beneficial effect of testosterone treatment on personality , psychological well-being , or mood .
Testosterone products are recommended by some prescribers in response to a diagnosis or presumption of " low testosterone " ( low-T ) for cardiovascular health , sexual function , muscle weakness or wasting , mood and behavior , and cognition .